L. Nalysnyk, J. Cid-ruzafa, and P. Rotella, Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature, European Respiratory Review, vol.21, issue.126, pp.355-61, 2012.
DOI : 10.1183/09059180.00002512

R. Hopkins, N. Burke, and C. Fell, Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada, European Respiratory Journal, vol.48, issue.1, 2016.
DOI : 10.1183/13993003.01504-2015

G. Raghu, H. Collard, and J. Egan, An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.6, pp.788-824, 2011.
DOI : 10.1378/chest.07-2488

V. Cottin, B. Crestani, and D. Valeyre, Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. ??labor??es par le centre national de r??f??rence et les centres de comp??tence pour les maladies pulmonaires rares sous l?????gide de la Soci??t?? de pneumologie de langue fran??aise, Revue des Maladies Respiratoires, vol.30, issue.10, pp.879-902, 2013.
DOI : 10.1016/j.rmr.2013.09.007
URL : https://hal.archives-ouvertes.fr/hal-01655039

H. Autorité-de-santé, Méthode « Recommandations pour la pratique clinique ». Saint-Denis: HAS, 2010.

J. Gribbin, R. Hubbard, L. Jeune, and I. , Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK, Thorax, vol.61, issue.11, pp.980-985, 2006.
DOI : 10.1136/thx.2006.062836

J. Scott, I. Johnston, and J. Britton, What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust., BMJ, vol.301, issue.6759, pp.1015-1022, 1990.
DOI : 10.1136/bmj.301.6759.1015

D. Mannino, R. Etzel, and R. Parrish, Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data., American Journal of Respiratory and Critical Care Medicine, vol.153, issue.5, pp.1548-52, 1996.
DOI : 10.1164/ajrccm.153.5.8630600

G. Raghu, T. Freudenberger, and S. Yang, High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis, European Respiratory Journal, vol.27, issue.1, pp.136-178, 2006.
DOI : 10.1183/09031936.06.00037005

W. Douglas, J. Ryu, and D. Schroeder, Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.157, issue.4, pp.1172-1180, 2000.
DOI : 10.1164/ajrccm.150.4.7921471

K. Jr, T. Tooze, J. Schwarz, and M. , Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model, Am J Respir Crit Care Med, vol.164, pp.1171-81, 2001.

V. Cottin and J. Cordier, Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis?, European Respiratory Journal, vol.40, issue.3, pp.519-540, 2012.
DOI : 10.1183/09031936.00001612

J. Sellares, F. Hernandez-gonzalez, and C. Lucena, Auscultation of Velcro Crackles is Associated With Usual Interstitial Pneumonia, Medicine, vol.95, issue.5, p.2573, 2016.
DOI : 10.1097/MD.0000000000002573

T. Watadani, F. Sakai, and T. Johkoh, Interobserver Variability in the CT Assessment of Honeycombing in the Lungs, Radiology, vol.266, issue.3, pp.936-980, 2013.
DOI : 10.1148/radiol.12112516

S. Walsh, L. Calandriello, and N. Sverzellati, Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT, Thorax, vol.71, issue.1, pp.45-51, 2016.
DOI : 10.1136/thoraxjnl-2015-207252

G. Raghu, D. Lynch, and J. Godwin, Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial, The Lancet Respiratory Medicine, vol.2, issue.4, pp.277-84, 2014.
DOI : 10.1016/S2213-2600(14)70011-6

G. Raghu, A. Wells, and A. Nicholson, Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria, American Journal of Respiratory and Critical Care Medicine, vol.46, issue.1, 2016.
DOI : 10.1183/13993003.02316-2014

V. Cottin, F. Capron, and P. Grenier, Pneumopathies interstitielles diffuses idiopathiques, Revue des Maladies Respiratoires, vol.21, issue.2, pp.299-318, 2004.
DOI : 10.1016/S0761-8425(04)71288-7

J. Chung, A. Chawla, and A. Peljto, CT Scan Findings of Probable Usual Interstitial Pneumonitis Have a High Predictive Value for Histologic Usual Interstitial Pneumonitis, Chest, vol.147, issue.2, pp.450-459, 2015.
DOI : 10.1378/chest.14-0976

J. Gruden, CT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond, American Journal of Roentgenology, vol.206, issue.3, pp.495-507, 2016.
DOI : 10.2214/AJR.15.15674

J. Hutchinson, A. Fogarty, and T. Mckeever, In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011, American Journal of Respiratory and Critical Care Medicine, vol.30, issue.10, pp.1161-1168, 2000.
DOI : 10.1016/S2213-2600(14)70101-8

J. Hutchinson, T. Mckeever, and A. Fogarty, Surgical lung biopsy for the diagnosis of interstitial lung disease in England, Eur Respir J, pp.1997-2008, 2016.

A. Babiak, J. Hetzel, and G. Krishna, Transbronchial Cryobiopsy: A New Tool for Lung Biopsies, Respiration, vol.78, issue.2, pp.203-211, 2009.
DOI : 10.1159/000203987

K. Johannson, V. Marcoux, and P. Ronksley, Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease: A Systematic Review and Meta-analysis, Annals of the American Thoracic Society, 2016.
DOI : 10.1513/AnnalsATS.201606-461SR

O. Ganganah, S. Guo, and M. Chiniah, Efficacy and safety of cryobiopsy versus forceps biopsy for interstitial lung diseases and lung tumours: A systematic review and meta-analysis, Respirology, vol.88, issue.Suppl 1, 2016.
DOI : 10.1155/2013/730574

V. Poletti and S. Benzaquen, Transbronchial cryobiopsy in diffuse parenchymal lung disease. A new star in the horizon, Sarcoidosis Vasc Diffuse Lung Dis, vol.31, pp.178-81, 2014.

E. Gershman, O. Fruchter, and F. Benjamin, Safety of Cryo-Transbronchial Biopsy in Diffuse Lung Diseases: Analysis of Three Hundred Cases, Respiration, vol.90, issue.1, pp.40-46, 2015.
DOI : 10.1159/000381921

V. Poletti, G. Casoni, and C. Gurioli, Lung cryobiopsies: A paradigm shift in diagnostic bronchoscopy?, Respirology, vol.162, issue.5, pp.645-54, 2014.
DOI : 10.1016/j.trsl.2013.06.004

S. Tomassetti, A. Wells, and U. Costabel, Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.31, issue.7, 2015.
DOI : 10.1164/rccm.200606-833OC

. American-thoracic-society, European respiratory society American thoracic societyEuropean respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, Am J Respir Crit Care Med, vol.165, pp.277-304, 2001.

F. Morell, A. Villar, and M. Montero, Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study, The Lancet Respiratory Medicine, vol.1, issue.9, pp.685-94, 2013.
DOI : 10.1016/S2213-2600(13)70191-7

Y. Jeong, K. Lee, and M. Chung, Chronic Hypersensitivity Pneumonitis and Pulmonary Sarcoidosis: Differentiation From Usual Interstitial Pneumonia Using High-Resolution Computed Tomography, Seminars in Ultrasound, CT and MRI, vol.35, issue.1, pp.47-58, 2014.
DOI : 10.1053/j.sult.2013.10.006

W. Wuyts, A. Cavazza, and G. Rossi, Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?, European Respiratory Review, vol.23, issue.133, pp.308-327, 2014.
DOI : 10.1183/09059180.00004914

J. Park, D. Kim, and I. Park, Prognosis of Fibrotic Interstitial Pneumonia, American Journal of Respiratory and Critical Care Medicine, vol.175, issue.7, pp.705-716, 2007.
DOI : 10.1002/art.21322

V. Cottin, Interstitial lung disease: are we missing formes frustes of connective tissue disease?, European Respiratory Journal, vol.28, issue.5, pp.893-899, 2006.
DOI : 10.1183/09031936.00101506

J. Lega, Q. Reynaud, and A. Belot, Idiopathic inflammatory myopathies and the lung, European Respiratory Review, vol.24, issue.136, pp.216-254, 2015.
DOI : 10.1183/16000617.00002015
URL : https://hal.archives-ouvertes.fr/hal-01594100

G. Foulon, P. Delaval, and D. Valeyre, ANCA-associated lung fibrosis: Analysis of 17 patients, Respiratory Medicine, vol.102, issue.10, pp.1392-1400, 2008.
DOI : 10.1016/j.rmed.2008.04.023
URL : https://hal.archives-ouvertes.fr/hal-00673305

B. Kang, J. Park, and J. Roh, Clinical Significance of Serum Autoantibodies in Idiopathic Interstitial Pneumonia, Journal of Korean Medical Science, vol.28, issue.5, pp.731-738, 2013.
DOI : 10.3346/jkms.2013.28.5.731

M. Kono, Y. Nakamura, and N. Enomoto, Usual Interstitial Pneumonia Preceding Collagen Vascular Disease: A Retrospective Case Control Study of Patients Initially Diagnosed with Idiopathic Pulmonary Fibrosis, PLoS ONE, vol.106, issue.4, p.94775, 2014.
DOI : 10.1371/journal.pone.0094775.t006

F. Bonella and U. Costabel, Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease, Seminars in Respiratory and Critical Care Medicine, vol.35, issue.02, pp.181-200, 2014.
DOI : 10.1055/s-0034-1371527

B. Ley, K. Brown, and H. Collard, Molecular biomarkers in idiopathic pulmonary fibrosis, AJP: Lung Cellular and Molecular Physiology, vol.307, issue.9, pp.681-91, 2014.
DOI : 10.1152/ajplung.00014.2014

R. Jenkins, J. Simpson, and G. Saini, Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study, The Lancet Respiratory Medicine, vol.3, issue.6, pp.462-72, 2015.
DOI : 10.1016/S2213-2600(15)00048-X

K. Meyer, G. Raghu, and R. Baughman, An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease, American Journal of Respiratory and Critical Care Medicine, vol.145, issue.9, pp.1004-1018, 2012.
DOI : 10.1136/thx.54.8.697

S. Ohshimo, F. Bonella, and A. Cui, Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.179, issue.11, pp.1043-1050, 2009.
DOI : 10.1183/09031936.03.00105202

R. Borie, C. Kannengiesser, and N. Nathan, Familial pulmonary fibrosis, Revue des Maladies Respiratoires, vol.32, issue.4, pp.413-447, 2015.
DOI : 10.1016/j.rmr.2014.07.017
URL : https://hal.archives-ouvertes.fr/hal-01595463

M. Steele, M. Speer, and J. Loyd, Clinical and Pathologic Features of Familial Interstitial Pneumonia, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.9, pp.1146-52, 2005.
DOI : 10.1164/ajrccm.164.9.2103074

H. Lee, J. Seo, and M. Steele, High-Resolution CT Scan Findings in Familial Interstitial Pneumonia Do Not Conform to Those of Idiopathic Interstitial Pneumonia, Chest, vol.142, issue.6, pp.1577-83, 2012.
DOI : 10.1378/chest.11-2812

H. Lee, J. Ryu, and M. Wittmer, Familial Idiopathic Pulmonary Fibrosis, Chest, vol.127, issue.6, pp.2034-2075, 2005.
DOI : 10.1378/chest.127.6.2034

C. Newton, K. Batra, and J. Torrealba, Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive, European Respiratory Journal, vol.48, issue.6, pp.1710-1730, 2016.
DOI : 10.1183/13993003.00308-2016

R. Borie, L. Tabeze, and G. Thabut, mutations in suspected genetic pulmonary fibrosis, European Respiratory Journal, vol.48, issue.6, pp.1721-1752, 2016.
DOI : 10.1183/13993003.02115-2015
URL : https://hal.archives-ouvertes.fr/hal-01467555

A. Diaz-de-leon, J. Cronkhite, and A. Katzenstein, Telomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations, PLoS ONE, vol.123, issue.5, p.10680, 2010.
DOI : 10.1371/journal.pone.0010680.s003

J. Cronkhite, C. Xing, and G. Raghu, Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.178, issue.7, pp.729-766, 2008.
DOI : 10.1086/500052

R. Borie, C. Kannengiesser, and S. Hirschi, Severe hematologic complications after lung transplantation in patients with telomerase complex mutations, The Journal of Heart and Lung Transplantation, vol.34, issue.4, pp.538-584, 2015.
DOI : 10.1016/j.healun.2014.11.010
URL : https://hal.archives-ouvertes.fr/hal-01146848

C. Van-moorsel, M. Van-oosterhout, and N. Barlo, Surfactant Protein C Mutations Are the Basis of a Significant Portion of Adult Familial Pulmonary Fibrosis in a Dutch Cohort, American Journal of Respiratory and Critical Care Medicine, vol.182, issue.11, pp.1419-1444, 2010.
DOI : 10.1136/thx.2004.026336

A. Diaz-de-leon, J. Cronkhite, and C. Yilmaz, Subclinical Lung Disease, Macrocytosis, and Premature Graying in Kindreds With Telomerase ( TERT ) Mutations, Chest, vol.140, issue.3, pp.753-63, 2011.
DOI : 10.1378/chest.10-2865

B. Stuart, J. Lee, and J. Kozlitina, Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation, The Lancet Respiratory Medicine, vol.2, issue.7, pp.557-65, 2014.
DOI : 10.1016/S2213-2600(14)70124-9

C. Garcia, Running Short on Time, Chest, vol.147, issue.6, pp.1450-1452, 2015.
DOI : 10.1378/chest.15-0077

S. Walsh, A. Wells, and S. Desai, Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study, The Lancet Respiratory Medicine, vol.4, issue.7, 2016.
DOI : 10.1016/S2213-2600(16)30033-9

D. Lamas, S. Kawut, and E. Bagiella, Delayed Access and Survival in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.127, issue.7, pp.842-849, 2011.
DOI : 10.1164/rccm.200210-1245OC

A. Wells, ???Any fool can make a rule and any fool will mind it???, BMC Medicine, vol.348, issue.2, p.23, 2016.
DOI : 10.1136/bmj.g3725

W. Travis, U. Costabel, and D. Hansell, An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias, American Journal of Respiratory and Critical Care Medicine, vol.39, issue.1, pp.733-781, 2013.
DOI : 10.1136/thx.2008.102814

K. Skolnik and C. Ryerson, Unclassifiable interstitial lung disease: A review, Respirology, vol.366, issue.Suppl. 5, pp.51-57, 2016.
DOI : 10.1056/NEJMoa1113354

B. Ley, H. Collard, K. Jr, and T. , Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.4, pp.431-471, 2011.
DOI : 10.1056/NEJMoa1002110

R. Bois, D. Weycker, and C. Albera, Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.184, issue.12, pp.1382-1391, 2011.
DOI : 10.1164/rccm.201007-1179OC

R. Bois, D. Weycker, and C. Albera, Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.9, pp.1231-1238, 2011.
DOI : 10.1183/09031936.00140507

R. Bois, D. Weycker, and C. Albera, Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.181, issue.4, pp.459-66, 2011.
DOI : 10.1164/rccm.200412-1756OC

B. Ley, C. Ryerson, and E. Vittinghoff, A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis, Annals of Internal Medicine, vol.156, issue.10, pp.684-91, 2012.
DOI : 10.7326/0003-4819-156-10-201205150-00004

B. Ley, W. Bradford, and D. Weycker, Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis, European Respiratory Journal, vol.45, issue.5, pp.1374-81, 2015.
DOI : 10.1183/09031936.00146314

M. Salisbury, M. Xia, and Y. Zhou, Idiopathic Pulmonary Fibrosis, Chest, vol.149, issue.2, 2015.
DOI : 10.1378/chest.15-0530

B. Ley, B. Elicker, and T. Hartman, Idiopathic Pulmonary Fibrosis: CT and Risk of Death, Radiology, vol.273, issue.2, pp.570-579, 2014.
DOI : 10.1148/radiol.14130216

A. Wells, S. Desai, and M. Rubens, Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.167, issue.7, pp.962-971, 2003.
DOI : 10.1148/radiology.217.3.r00nv31701
URL : https://hal.archives-ouvertes.fr/hal-00499159

S. Schmidt, N. Tayob, and M. Han, Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function, Chest, vol.145, issue.3, pp.579-85, 2014.
DOI : 10.1378/chest.13-0844

C. Zappala, P. Latsi, and A. Nicholson, Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis, European Respiratory Journal, vol.35, issue.4, pp.830-836, 2010.
DOI : 10.1183/09031936.00155108

L. Richeldi, C. Ryerson, and J. Lee, Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis, Thorax, vol.67, issue.5, pp.407-418, 2012.
DOI : 10.1136/thoraxjnl-2011-201184

A. Wells, Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear, Thorax, vol.68, issue.4, 2012.
DOI : 10.1136/thoraxjnl-2012-202640

B. Aguilaniu, EFX et pneumopathies interstitielles diffuses : qu'en attendre et quelle place dans la prise en charge ?, Lett Pneumol, vol.19, pp.17-20, 2016.

A. Holland, Review series: Aspects of interstitial lung disease: Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options, Chronic Respiratory Disease, vol.40, issue.135, pp.101-112, 2010.
DOI : 10.1111/j.1475-6773.2005.0k375.x

N. Carter, Pirfenidone, Drugs, vol.183, issue.4, pp.1721-1753, 2011.
DOI : 10.1164/rccm.201006-0894CI

G. Raghu, W. Johnson, and D. Lockhart, Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone, American Journal of Respiratory and Critical Care Medicine, vol.33, issue.4, pp.1061-1070, 1999.
DOI : 10.1097/00000478-199402000-00003

A. Azuma, T. Nukiwa, and E. Tsuboi, Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.171, issue.9, pp.1040-1047, 2005.
DOI : 10.1056/NEJMcpc020028

H. Taniguchi, M. Ebina, and Y. Kondoh, Pirfenidone in idiopathic pulmonary fibrosis, European Respiratory Journal, vol.35, issue.4, pp.821-830, 2010.
DOI : 10.1183/09031936.00005209

P. Noble, C. Albera, and W. Bradford, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, The Lancet, vol.377, issue.9779, pp.1760-1769, 2011.
DOI : 10.1016/S0140-6736(11)60405-4
URL : https://hal.archives-ouvertes.fr/hal-00873255

K. Jr, T. Bradford, W. Castro-bernardini, and S. , A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2083-92, 2014.

C. Vancheri and R. Bois, A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer, European Respiratory Journal, vol.41, issue.2, pp.262-271, 2013.
DOI : 10.1183/09031936.00115112

P. Spagnolo, D. Giovane, C. Luppi, and F. , Non-steroid agents for idiopathic pulmonary fibrosis, Cochrane Database Syst Rev, vol.99, issue.3, p.3134, 2010.
DOI : 10.1002/14651858.CD003134

D. Lederer, W. Bradford, and E. Fagan, Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis, Chest, vol.148, issue.1, pp.196-201, 2015.
DOI : 10.1378/chest.14-2817

P. Noble, C. Albera, and W. Bradford, Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials, European Respiratory Journal, vol.47, issue.1, pp.243-53, 2016.
DOI : 10.1183/13993003.00026-2015

K. Sugino, F. Ishida, and N. Kikuchi, Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone, Respirology, vol.38, issue.2, pp.239-284, 2014.
DOI : 10.1183/09031936.00114010

T. Iwasawa, T. Ogura, and F. Sakai, CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis, European Journal of Radiology, vol.83, issue.1, pp.32-40, 2014.
DOI : 10.1016/j.ejrad.2012.02.014

B. Loeh, F. Drakopanagiotakis, and G. Bandelli, Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.191, issue.1, pp.110-113, 2015.
DOI : 10.1371/journal.pone.0073279

S. Harari, A. Caminati, and C. Albera, Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study, Respiratory Medicine, vol.109, issue.7, pp.904-917, 2015.
DOI : 10.1016/j.rmed.2015.04.010

U. Oltmanns, N. Kahn, and K. Palmowski, Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases, Respiration, vol.88, issue.3, 2014.
DOI : 10.1159/000363064

M. Kreuter, Pirfenidone: an update on clinical trial data and insights from everyday practice, European Respiratory Review, vol.23, issue.131, pp.111-118, 2014.
DOI : 10.1183/09059180.00008513

U. Costabel, C. Albera, and W. Bradford, Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis, Sarcoid Vasc Diffuse Lung Dis, vol.31, pp.198-205, 2014.

D. Valeyre, C. Albera, and W. Bradford, Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis, Respirology, vol.15, issue.9, pp.740-747, 2014.
DOI : 10.1002/pds.1211

C. Jiang, H. Huang, and J. Liu, Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials, PLoS ONE, vol.7, issue.10, p.47024, 2012.
DOI : 10.1371/journal.pone.0047024.s001

J. Behr, M. Kreuter, and M. Hoeper, Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry, European Respiratory Journal, vol.46, issue.1, pp.186-96, 2015.
DOI : 10.1183/09031936.00217614

U. Costabel, E. Bendstrup, and V. Cottin, Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events, Advances in Therapy, vol.184, issue.4, pp.375-91, 2014.
DOI : 10.1164/rccm.201101-0138OC

F. Grimminger, A. Gunther, and C. Vancheri, The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis, European Respiratory Journal, vol.45, issue.5, pp.1426-1459, 2015.
DOI : 10.1183/09031936.00149614

L. Wollin, I. Maillet, and V. Quesniaux, Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis, Journal of Pharmacology and Experimental Therapeutics, vol.349, issue.2, pp.209-229, 2014.
DOI : 10.1124/jpet.113.208223

L. Wollin, E. Wex, and A. Pautsch, Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis, European Respiratory Journal, vol.45, issue.5, pp.1434-1479, 2015.
DOI : 10.1183/09031936.00174914

K. Hostettler, J. Zhong, and E. Papakonstantinou, Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis, Respiratory Research, vol.25, issue.3, p.157, 2014.
DOI : 10.1016/j.cytogfr.2014.03.003

S. Rangarajan, A. Kurundkar, and D. Kurundkar, Novel Mechanisms for the Antifibrotic Action of Nintedanib, American Journal of Respiratory Cell and Molecular Biology, vol.2, issue.1, pp.51-60, 2016.
DOI : 10.4161/auto.7.11.17652

L. Richeldi, U. Costabel, and M. Selman, Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis, New England Journal of Medicine, vol.365, issue.12, pp.1079-87, 2011.
DOI : 10.1056/NEJMoa1103690

L. Richeldi, V. Cottin, and K. Flaherty, Design of the INPULSIS??? trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis, Respiratory Medicine, vol.108, issue.7, pp.1023-1053, 2014.
DOI : 10.1016/j.rmed.2014.04.011

L. Richeldi, R. Bois, and G. Raghu, Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis, New England Journal of Medicine, vol.370, issue.22, pp.2071-82, 2014.
DOI : 10.1056/NEJMoa1402584

U. Costabel, Y. Inoue, and L. Richeldi, Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS, American Journal of Respiratory and Critical Care Medicine, vol.191, issue.2, pp.178-85, 2016.
DOI : 10.1164/rccm.201411-2044ED

M. Kolb, L. Richeldi, and J. Behr, Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume, Thorax, vol.48, issue.Suppl 60, 2016.
DOI : 10.1136/thoraxjnl-2016-208710

V. Cottin, Nintedanib: a new treatment for idiopathic pulmonary fibrosis, Clinical Investigation, vol.5, issue.7, pp.621-653, 2015.
DOI : 10.4155/cli.15.27

W. Wuyts, M. Kolb, and S. Stowasser, First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of?????50??% of Predicted Value, Lung, vol.191, issue.Suppl 59, pp.739-782, 2016.
DOI : 10.1183/13993003.congress-2015.OA4499

L. Richeldi, V. Cottin, and R. Bois, Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS?? trials, Respiratory Medicine, vol.113, 2016.
DOI : 10.1016/j.rmed.2016.02.001

I. Delanote, W. Wuyts, and J. Yserbyt, Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series, BMC Pulmonary Medicine, vol.35, issue.4, p.156, 2016.
DOI : 10.1016/j.healun.2016.01.010

C. Albera, U. Costabel, and E. Fagan, Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function, European Respiratory Journal, vol.48, issue.3, pp.843-51, 2016.
DOI : 10.1183/13993003.01966-2015

M. Demedts, J. Behr, and R. Buhl, High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis, New England Journal of Medicine, vol.353, issue.21, pp.2229-2271, 2005.
DOI : 10.1056/NEJMoa042976

G. Raghu, K. Anstrom, K. Jr, and T. , Prednisone, azathioprine , and N-acetylcysteine for pulmonary fibrosis, N Engl J Med, vol.366, 2012.

J. Oldham, S. Ma, and F. Martinez, -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.124, issue.12, pp.1475-82, 2015.
DOI : 10.1056/NEJMc1013504

J. Behr, E. Bendstrup, and B. Crestani, Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet Respiratory Medicine, vol.4, issue.6, pp.445-53, 2016.
DOI : 10.1016/S2213-2600(16)30044-3

S. Nagai, M. Kitaichi, and K. Hamada, Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF, Sarcoid Vasc Diffuse Lung Dis, vol.16, pp.209-223, 1999.

S. Gay, E. Kazerooni, and G. Toews, Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.162, issue.4, pp.1063-72, 1998.
DOI : 10.1164/ajrccm.149.6.8004317

R. Winterbauer, S. Hammar, and K. Hallman, Diffuse interstitial pneumonitis, The American Journal of Medicine, vol.65, issue.4, pp.661-72, 1978.
DOI : 10.1016/0002-9343(78)90855-0

G. Raghu, W. Depaso, and K. Cain, Azathioprine Combined with Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Prospective Double-blind, Randomized, Placebo-controlled Clinical Trial, American Review of Respiratory Disease, vol.102, issue.1, pp.291-297, 1991.
DOI : 10.1136/thx.44.4.280

M. Johnson, S. Kwan, and N. Snell, Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis., Thorax, vol.44, issue.4, pp.280-288, 1989.
DOI : 10.1136/thx.44.4.280

H. Collard, J. Ryu, and W. Douglas, Combined Corticosteroid and Cyclophosphamide Therapy Does Not Alter Survival in Idiopathic Pulmonary Fibrosis, Chest, vol.125, issue.6, pp.2169-74, 2004.
DOI : 10.1378/chest.125.6.2169

C. Pereira, T. Malheiros, and E. Coletta, Survival in idiopathic pulmonary fibrosis???cytotoxic agents compared to corticosteroids, Respiratory Medicine, vol.100, issue.2, pp.340-347, 2006.
DOI : 10.1016/j.rmed.2005.05.008

B. Hope-gill, S. Hilldrup, and C. Davies, A Study of the Cough Reflex in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.8, pp.995-1002, 2003.
DOI : 10.1164/ajrccm/145.5.1191

H. Kubo, K. Nakayama, and M. Yanai, Anticoagulant Therapy for Idiopathic Pulmonary Fibrosis, Chest, vol.128, issue.3, pp.1475-82, 2005.
DOI : 10.1378/chest.128.3.1475

I. Noth, K. Anstrom, and S. Calvert, A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.111, issue.1
DOI : 10.1186/1465-9921-10-101

M. Kreuter, M. Wijsenbeek, and M. Vasakova, Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis, European Respiratory Journal, vol.47, issue.6, pp.1776-84, 2016.
DOI : 10.1183/13993003.02087-2015

E. Fiorucci, G. Lucantoni, and G. Paone, Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens, Eur Rev Med Pharmacol Sci, vol.12, pp.105-116, 2008.

K. Antoniou, A. Nicholson, and M. Dimadi, Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis, European Respiratory Journal, vol.28, issue.3, pp.496-504, 2006.
DOI : 10.1183/09031936.06.00032605

W. Douglas, J. Ryu, and S. Swensen, Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.187, issue.1, pp.220-225, 1998.
DOI : 10.1378/chest.110.2.378

A. Grgic, H. Lausberg, and M. Heinrich, Progression of Fibrosis in Usual Interstitial Pneumonia: Serial Evaluation of the Native Lung after Single Lung Transplantation, Respiration, vol.68, issue.2, pp.139-184, 2008.
DOI : 10.1159/000064006

M. Wahidi, J. Ravenel, and S. Palmer, Progression of Idiopathic Pulmonary Fibrosis in Native Lungs After Single Lung Transplantation, Chest, vol.121, issue.6, pp.2072-2078, 2002.
DOI : 10.1378/chest.121.6.2072

G. Raghu, K. Brown, and W. Bradford, A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis, New England Journal of Medicine, vol.350, issue.2, pp.125-158, 2004.
DOI : 10.1056/NEJMoa030511

K. Jr, T. Albera, C. Bradford, and W. , Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial, Lancet, vol.374, pp.222-230, 2009.

K. Jr, T. Behr, J. Brown, and K. , BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, vol.177, pp.75-81, 2008.

K. Jr, T. Brown, K. Raghu, and G. , BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis

G. Raghu, R. Million-rousseau, and A. Morganti, Efficacy And Safety Of Macitentan In Idiopathic Pulmonary Fibrosis: Results Of A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial, B93. CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS AND SARCOIDOSIS, p.3631, 2012.
DOI : 10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A3631

G. Raghu, J. Behr, and K. Egan, ARTEMIS-IPF: A Placebo-Controlled Trial Of Ambrisentan In Idiopathic Pulmonary Fibrosis, B93. CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS AND SARCOIDOSIS, p.3632, 2012.
DOI : 10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A3632

G. Raghu, K. Brown, and U. Costabel, Treatment of Idiopathic Pulmonary Fibrosis with Etanercept, American Journal of Respiratory and Critical Care Medicine, vol.178, issue.9, pp.948-55, 2008.
DOI : 10.1056/NEJMoa030511

G. Raghu, F. Martinez, and K. Brown, CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab, European Respiratory Journal, vol.46, issue.6, pp.1740-50, 2015.
DOI : 10.1183/13993003.01558-2014

G. Raghu, K. Brown, and H. Collard, Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial, The Lancet Respiratory Medicine, vol.5, issue.1, pp.22-32, 2017.
DOI : 10.1016/S2213-2600(16)30421-0

D. Mason, M. Brizzio, and J. Alster, Lung Transplantation for Idiopathic Pulmonary Fibrosis, The Annals of Thoracic Surgery, vol.84, issue.4, pp.1121-1129, 2007.
DOI : 10.1016/j.athoracsur.2007.04.096

D. Keating, B. Levvey, and T. Kotsimbos, Lung Transplantation in Pulmonary Fibrosis: Challenging Early Outcomes Counterbalanced by Surprisingly Good Outcomes Beyond 15 Years, Transplantation Proceedings, vol.41, issue.1, pp.289-91, 2009.
DOI : 10.1016/j.transproceed.2008.10.042

G. Thabut, H. Mal, and Y. Castier, Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis, The Journal of Thoracic and Cardiovascular Surgery, vol.126, issue.2, pp.469-75, 2003.
DOI : 10.1016/S0022-5223(03)00600-7

D. Weill, C. Benden, and P. Corris, A consensus document for the selection of lung transplant candidates: 2014???An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.34, issue.1, pp.1-15, 2015.
DOI : 10.1016/j.healun.2014.06.014

G. Thabut, J. Christie, and P. Ravaud, Survival After Bilateral Versus Single-Lung Transplantation for Idiopathic Pulmonary Fibrosis, Annals of Internal Medicine, vol.151, issue.11, pp.767-74, 2009.
DOI : 10.7326/0003-4819-151-11-200912010-00004

D. Chauhan, A. Karanam, and A. Merlo, Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation, The Journal of Heart and Lung Transplantation, vol.35, issue.5, pp.657-60, 2016.
DOI : 10.1016/j.healun.2015.12.030

M. Horton, S. Danoff, and N. Lechtzin, Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis, Thorax, vol.63, issue.8, p.749, 2008.
DOI : 10.1136/thx.2008.098699

M. Horton, V. Santopietro, and L. Mathew, Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis, Annals of Internal Medicine, vol.157, issue.6, pp.398-406, 2012.
DOI : 10.7326/0003-4819-157-6-201209180-00003

C. Kilduff, M. Counter, and G. Thomas, Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study, Cough, vol.10, issue.1, p.4, 2014.
DOI : 10.1378/chest.10-0438

B. Vainshelboim, J. Oliveira, and B. Fox, Long-Term Effects of a 12-Week Exercise Training Program on Clinical Outcomes in Idiopathic Pulmonary Fibrosis, Lung, vol.17, issue.3, pp.345-54, 2015.
DOI : 10.1111/j.1365-2281.1997.tb00008.x

B. Vainshelboim, J. Oliveira, and L. Yehoshua, Exercise Training-Based Pulmonary Rehabilitation Program Is Clinically Beneficial for Idiopathic Pulmonary Fibrosis, Respiration, vol.88, issue.5, pp.378-88, 2014.
DOI : 10.1159/000367899

K. Kenn, R. Gloeckl, and J. Behr, Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis - A Review, Respiration, vol.86, issue.2, pp.89-99, 2013.
DOI : 10.1159/000354112

L. Dowman, C. Hill, and A. Holland, Pulmonary rehabilitation for interstitial lung disease, Cochrane Database Syst Rev, vol.63, issue.4, p.6322, 2014.
DOI : 10.1002/14651858.CD006322.pub2

D. Morrison and J. Stovall, Increased Exercise Capacity in Hypoxemic Patients after Long-term Oxygen Therapy, Chest, vol.102, issue.2, pp.542-50, 1992.
DOI : 10.1378/chest.102.2.542

D. Visca, A. Montgomery, and A. De-lauretis, Ambulatory oxygen in interstitial lung disease, European Respiratory Journal, vol.38, issue.4, pp.987-90, 2011.
DOI : 10.1183/09031936.00190710

R. Frank, S. Hicks, and A. Duck, Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit?: Table 1???, European Respiratory Journal, vol.40, issue.1, pp.269-70, 2012.
DOI : 10.1183/09031936.00007712

O. Nishiyama, H. Miyajima, and Y. Fukai, Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia, Respiratory Medicine, vol.107, issue.8, pp.1241-1247, 2013.
DOI : 10.1016/j.rmed.2013.05.015

A. Jennings, A. Davies, and J. Higgins, A systematic review of the use of opioids in the management of dyspnoea, Thorax, vol.57, issue.11, pp.939-983, 2002.
DOI : 10.1136/thorax.57.11.939

C. Kohberg, C. Andersen, and E. Bendstrup, Opioids: an unexplored option for treatment of dyspnea in IPF, European Clinical Respiratory Journal, vol.4, issue.1, p.30629, 2016.
DOI : 10.1183/09031936.05.00021005

S. Allen, S. Raut, and J. Woollard, Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis, Palliative Medicine, vol.4, issue.2, pp.128-158, 2005.
DOI : 10.1136/bmj.327.7414.523

A. Holland, C. Hill, and M. Conron, Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease, Thorax, vol.63, issue.6, pp.549-54, 2008.
DOI : 10.1136/thx.2007.088070

O. Nishiyama, Y. Kondoh, and T. Kimura, Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response, Respirology Chest, vol.13168135, pp.442-449, 2008.

A. Holland, C. Hill, and I. Glaspole, Predictors of benefit following pulmonary rehabilitation for interstitial lung disease, Respiratory Medicine, vol.106, issue.3, pp.429-464, 2012.
DOI : 10.1016/j.rmed.2011.11.014

C. Ryerson, C. Cayou, and F. Topp, Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: A prospective cohort study, Respiratory Medicine, vol.108, issue.1, pp.203-213, 2014.
DOI : 10.1016/j.rmed.2013.11.016

R. Kozu, H. Senjyu, and S. Jenkins, Differences in Response to Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease, Respiration, vol.71, issue.3, pp.196-205, 2011.
DOI : 10.1159/000077422

P. Huppmann, B. Sczepanski, and M. Boensch, Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease, European Respiratory Journal, vol.42, issue.2, 2012.
DOI : 10.1183/09031936.00081512

B. Rammaert, S. Leroy, and B. Cavestri, Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis, Revue des Maladies Respiratoires, vol.28, issue.7, pp.275-82, 2009.
DOI : 10.1016/j.rmr.2011.06.006

C. Taillé, Où meurent les patients atteints de fibrose pulmonaire idiopathique ? Info Respir, 2015.

Z. Ahmadi, N. Wysham, and S. Lundstrom, End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study, Thorax, vol.11, issue.6, pp.510-516, 2016.
DOI : 10.6004/jnccn.2013.0029

S. Bajwah, J. Ross, and A. Wells, Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention, Thorax, vol.63, issue.(Suppl 5), pp.830-839, 2015.
DOI : 10.3111/13696998.2012.680553

A. Abernethy, C. Mcdonald, and P. Frith, Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial, The Lancet, vol.376, issue.9743, pp.784-93, 2010.
DOI : 10.1016/S0140-6736(10)61115-4

H. Collard, C. Ryerson, and T. Corte, Acute Exacerbations of Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.176, issue.7, pp.265-75, 2016.
DOI : 10.1378/chest.120.1.213

A. Brown, C. Fischer, and O. Shlobin, Outcomes After Hospitalization in Idiopathic Pulmonary Fibrosis, Chest, vol.147, issue.1, pp.173-182, 2015.
DOI : 10.1378/chest.13-2424

F. Luppi, S. Cerri, and S. Taddei, Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review, Internal and Emergency Medicine, vol.20, issue.4, pp.401-412, 2015.
DOI : 10.1097/MCP.0000000000000073

K. Johannson, E. Vittinghoff, and K. Lee, Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure, European Respiratory Journal, vol.43, issue.4, pp.1124-1155, 2014.
DOI : 10.1183/09031936.00122213

H. Collard, B. Moore, and K. Flaherty, Acute Exacerbations of Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.176, issue.7, pp.636-679, 2007.
DOI : 10.1378/chest.120.1.213

G. Raghu, Idiopathic Pulmonary Fibrosis: Increased Survival with ???Gastroesophageal Reflux Therapy???, American Journal of Respiratory and Critical Care Medicine, vol.184, issue.12, pp.1330-1332, 2011.
DOI : 10.1164/rccm.201101-0138OC

E. Morawiec, I. Tillie-leblond, and V. Pansini, Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses, European Respiratory Journal, vol.38, issue.6, pp.1487-1496, 2011.
DOI : 10.1183/09031936.00127311

?. Assistance-publique and P. Hôpitaux-de, Cyclophosphamide for acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP); 2016 Available from: https://clinicaltrials. gov/ct2/show, p.1

L. Richeldi, Time for prevention of idiopathic pulmonary fibrosis exacerbation, Ann Am Thorac Soc, vol.12, pp.181-186, 2015.

F. Trudzinski, F. Kaestner, and H. Schafers, Outcome of Patients with Interstitial Lung Disease Treated with Extracorporeal Membrane Oxygenation for Acute Respiratory Failure, American Journal of Respiratory and Critical Care Medicine, vol.8, issue.5
DOI : 10.1164/rccm.200611-1739OC

S. Blivet, F. Philit, and J. Sab, Outcome of Patients With Idiopathic Pulmonary Fibrosis Admitted to the ICU for Respiratory Failure, Chest, vol.120, issue.1, pp.209-221, 2001.
DOI : 10.1378/chest.120.1.209

D. Kim, J. Park, and B. Park, Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features, European Respiratory Journal, vol.27, issue.1, pp.143-50, 2006.
DOI : 10.1183/09031936.06.00114004

M. Molina-molina, J. Badia, and A. Marin-arguedas, Caracter??sticas cl??nicas y pron??stico de los pacientes con fibrosis pulmonar que ingresan en cuidados intensivos por insuficiencia respiratoria. An??lisis de 20 casos, Medicina Cl??nica, vol.121, issue.2, pp.63-70, 2003.
DOI : 10.1016/S0025-7753(03)73856-1

G. Saydain, A. Islam, and B. Afessa, Outcome of Patients with Idiopathic Pulmonary Fibrosis Admitted to the Intensive Care Unit, American Journal of Respiratory and Critical Care Medicine, vol.166, issue.6, pp.839-881, 2002.
DOI : 10.1136/thx.54.5.390

S. Nava and F. Rubini, Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis, Thorax, vol.54, issue.5, pp.390-395, 1999.
DOI : 10.1136/thx.54.5.390

J. Stern, H. Mal, and O. Groussard, Prognosis of Patients With Advanced Idiopathic Pulmonary Fibrosis Requiring Mechanical Ventilation for Acute Respiratory Failure, Chest, vol.120, issue.1, pp.213-222, 2001.
DOI : 10.1378/chest.120.1.213

F. Al-hameed and S. Sharma, Outcome of Patients Admitted to Intensive Care Unit for Acute Exacerbation of Idiopathic Pulmonary Fibrosis, Canadian Respiratory Journal, vol.11, issue.2, pp.117-139, 2004.
DOI : 10.1155/2004/379723

T. Fumeaux, C. Rothmeier, and P. Jolliet, Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis, Intensive Care Medicine, vol.27, issue.12, pp.1868-74, 2001.
DOI : 10.1007/s00134-001-1150-0

C. Mollica, G. Paone, and V. Conti, Mechanical Ventilation in Patients with End-Stage Idiopathic Pulmonary Fibrosis, Respiration, vol.79, issue.3, pp.209-224, 2010.
DOI : 10.1159/000225932

P. Rangappa and J. Moran, Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis, Crit Care Resusc, vol.11, pp.102-111, 2009.

S. Mallick, Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit, Respiratory Medicine, vol.102, issue.10, pp.1355-1364, 2008.
DOI : 10.1016/j.rmed.2008.06.003

B. Rush, K. Wiskar, and L. Berger, The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis, Respiratory Medicine, vol.111, pp.72-78, 2016.
DOI : 10.1016/j.rmed.2015.12.005

S. Gaudry, F. Vincent, and A. Rabbat, Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia, The Journal of Thoracic and Cardiovascular Surgery, vol.147, issue.1, pp.47-53, 2014.
DOI : 10.1016/j.jtcvs.2013.06.039

T. Yokoyama, Y. Kondoh, and H. Taniguchi, Noninvasive Ventilation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis, Internal Medicine, vol.49, issue.15, pp.1509-1523, 2010.
DOI : 10.2169/internalmedicine.49.3222

A. Mullier, V. Cottin, and J. Richard, Fibrose pulmonaire : dans quels cas et sur quels critères envisager une admission en réanimation ? Reanimation 2013, pp.45-53

S. Nathan and V. Cottin, Pulmonary hypertension in patients with idiopathic pulmonary fibrosis, Eur Respir Mon, vol.57, pp.148-60, 2012.
DOI : 10.1183/1025448x.10019511

A. Shorr, J. Wainright, and C. Cors, Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant, European Respiratory Journal, vol.30, issue.4, pp.715-736, 2007.
DOI : 10.1183/09031936.00107206

C. Lettieri, S. Nathan, and S. Barnett, Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis, Chest, vol.129, issue.3, pp.746-52, 2006.
DOI : 10.1378/chest.129.3.746

E. Judge, A. Fabre, and H. Adamali, Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis, European Respiratory Journal, vol.40, issue.1, pp.93-100, 2012.
DOI : 10.1183/09031936.00115511

S. Nathan, O. Shlobin, and S. Barnett, Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis, Respiratory Medicine, vol.102, issue.9, pp.1305-1315, 2008.
DOI : 10.1016/j.rmed.2008.03.022

K. Swanson, J. Utz, and M. Krowka, Doppler echocardiographyright heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension, Med Sci Monit, vol.14, pp.177-82, 2008.

S. Arcasoy, J. Christie, and V. Ferrari, Echocardiographic Assessment of Pulmonary Hypertension in Patients with Advanced Lung Disease, American Journal of Respiratory and Critical Care Medicine, vol.167, issue.5, pp.735-775, 2003.
DOI : 10.1164/rccm.2107027

A. Devaraj, A. Wells, and M. Meister, The Effect of Diffuse Pulmonary Fibrosis on the Reliability of CT Signs of Pulmonary Hypertension, Radiology, vol.249, issue.3, pp.1042-1051, 2008.
DOI : 10.1148/radiol.2492080269

H. Leuchte, R. Baumgartner, and M. Nounou, Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease, American Journal of Respiratory and Critical Care Medicine, vol.173, issue.7, pp.744-50, 2006.
DOI : 10.1164/rccm.200401-006OC

D. Zisman, A. Karlamangla, and S. Kawut, Validation of a Method To Screen for Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis, Chest, vol.133, issue.3, pp.640-645, 2008.
DOI : 10.1378/chest.07-2488

N. Galie, M. Humbert, and J. Vachiery, 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, European Respiratory Journal, vol.46, issue.4, pp.903-75, 2015.
DOI : 10.1183/13993003.01032-2015

W. Seeger, Y. Adir, and J. Barbera, Pulmonary Hypertension in Chronic Lung Diseases, Journal of the American College of Cardiology, vol.62, issue.25, pp.109-125, 2013.
DOI : 10.1016/j.jacc.2013.10.036

S. Nathan and C. King, Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?, Drug Design, Development and Therapy, vol.8, pp.875-85, 2014.
DOI : 10.2147/DDDT.S64907

O. Minai, D. Sahoo, and J. Chapman, Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease, Respiratory Medicine, vol.102, issue.7, pp.1015-1035, 2008.
DOI : 10.1016/j.rmed.2008.02.002

T. Corte, G. Keir, and K. Dimopoulos, Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia, American Journal of Respiratory and Critical Care Medicine, vol.145, issue.2, pp.208-225, 2014.
DOI : 10.1183/09031936.00011308

G. Raghu, S. Nathan, and J. Behr, Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction, European Respiratory Journal, vol.46, issue.5, pp.1370-1377, 2015.
DOI : 10.1183/13993003.01537-2014

H. Ghofrani, R. Wiedemann, and F. Rose, Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial, The Lancet, vol.360, issue.9337, pp.895-900, 2002.
DOI : 10.1016/S0140-6736(02)11024-5

B. Madden, M. Allenby, and T. Loke, A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease, Vascular Pharmacology, vol.44, issue.5, pp.372-378, 2006.
DOI : 10.1016/j.vph.2006.01.013

H. Collard, K. Anstrom, and M. Schwarz, Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis, Chest, vol.131, issue.3, pp.897-906, 2007.
DOI : 10.1378/chest.06-2101

D. Zisman, M. Schwarz, and K. Anstrom, A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis, N Engl J Med, vol.363, pp.620-628, 2010.

M. Han, D. Bach, and P. Hagan, Sildenafil Preserves Exercise Capacity in Patients With Idiopathic Pulmonary Fibrosis and Right-sided Ventricular Dysfunction, Chest, vol.143, issue.6, pp.1699-708, 2013.
DOI : 10.1378/chest.12-1594

M. Hoeper, J. Behr, and M. Held, Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias, PLOS ONE, vol.42, issue.6, p.141911, 2015.
DOI : 10.1371/journal.pone.0141911.t004

M. Hoeper, M. Halank, and H. Wilkens, Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial, European Respiratory Journal, vol.41, issue.4, pp.853-60, 2013.
DOI : 10.1183/09031936.00213911

E. Savarino, R. Carbone, and E. Marabotto, Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients, European Respiratory Journal, vol.42, issue.5, pp.1322-1353, 2013.
DOI : 10.1183/09031936.00101212

I. Noth, S. Zangan, and R. Soares, Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis, European Respiratory Journal, vol.39, issue.2, pp.344-51, 2012.
DOI : 10.1183/09031936.00099910

C. Tossier, C. Dupin, and L. Plantier, Hiatal hernia on thoracic computed tomography in pulmonary fibrosis, European Respiratory Journal, vol.48, issue.3, pp.833-875, 2016.
DOI : 10.1183/13993003.01796-2015

R. Tobin, C. Pope, and C. Pellegrini, Increased Prevalence of Gastroesophageal Reflux in Patients with Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.91, issue.6, pp.1804-1812, 1998.
DOI : 10.1378/chest.99.6.1330

M. Sweet, M. Patti, and L. Leard, Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation, The Journal of Thoracic and Cardiovascular Surgery, vol.133, issue.4, pp.1078-84, 2007.
DOI : 10.1016/j.jtcvs.2006.09.085

C. Tcherakian, V. Cottin, and P. Brillet, Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease, Thorax, vol.66, issue.3, pp.226-257, 2011.
DOI : 10.1136/thx.2010.137190

J. Lee, H. Collard, and G. Raghu, Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis?, The American Journal of Medicine, vol.123, issue.4, pp.304-315, 2010.
DOI : 10.1016/j.amjmed.2009.07.033

P. Linden, R. Gilbert, and B. Yeap, Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation, The Journal of Thoracic and Cardiovascular Surgery, vol.131, issue.2, pp.438-484, 2006.
DOI : 10.1016/j.jtcvs.2005.10.014

J. Lee, J. Ryu, and B. Elicker, Gastroesophageal Reflux Therapy Is Associated with Longer Survival in Patients with Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.184, issue.12, pp.1390-1394, 2011.
DOI : 10.1164/rccm.200808-1359OC

G. Raghu and K. Meyer, Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy?, European Respiratory Journal, vol.39, issue.2, pp.242-247, 2012.
DOI : 10.1183/09031936.00211311

J. Lee, H. Collard, and K. Anstrom, Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials, The Lancet Respiratory Medicine, vol.1, issue.5, pp.369-76, 2013.
DOI : 10.1016/S2213-2600(13)70105-X

M. Kreuter, W. Wuyts, and E. Renzoni, Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis, The Lancet Respiratory Medicine, vol.4, issue.5, 2016.
DOI : 10.1016/S2213-2600(16)00067-9

K. Devault and D. Castell, Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease, The American Journal of Gastroenterology, vol.59, issue.1, pp.190-200, 2005.
DOI : 10.1111/j.1572-0241.2003.08109.x

T. Arai, Y. Inoue, and Y. Sasaki, Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis, Respiratory Investigation, vol.52, issue.2, pp.136-179, 2014.
DOI : 10.1016/j.resinv.2013.09.002

M. Mejia, G. Carrillo, and J. Rojas-serrano, Idiopathic Pulmonary Fibrosis and Emphysema, Chest, vol.136, issue.1, pp.10-15, 2009.
DOI : 10.1378/chest.08-2306

V. Cottin, H. Nunes, and P. Brillet, Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity, European Respiratory Journal, vol.26, issue.4, pp.586-93, 2005.
DOI : 10.1183/09031936.05.00021005

V. Cottin, L. Pavec, J. Prevot, and G. , Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome, European Respiratory Journal, vol.35, issue.1, pp.105-116, 2010.
DOI : 10.1183/09031936.00038709
URL : https://hal.archives-ouvertes.fr/hal-01608607

V. Cottin and J. Cordier, Combined Pulmonary Fibrosis and Emphysema: An Experimental and Clinically Relevant Phenotype, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.12, p.1605, 2005.
DOI : 10.1164/ajrccm.150.3.8087340

T. Akagi, T. Matsumoto, and T. Harada, Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis, Respiratory Medicine, vol.103, issue.8, pp.1209-1224, 2009.
DOI : 10.1016/j.rmed.2009.02.001

S. Schmidt, A. Nambiar, and N. Tayob, Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema, European Respiratory Journal, vol.38, issue.1, pp.176-83, 2011.
DOI : 10.1183/09031936.00114010

V. Cottin, H. Taniguchi, and L. Richeldi, Effect of baseline emphysema on reduction in FVC decline with nintedanib in the Inpulsis(trials. In: 18th International colloquium on lung and airway fibrosis, 2014.

M. Clark, B. Cooper, and S. Singh, A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis, Thorax, vol.56, issue.6, pp.482-488, 2001.
DOI : 10.1136/thorax.56.6.482

M. Aydogdu, B. Ciftci, F. Guven, and S. , Assessment of sleep with polysomnography in patients with interstitial lung disease] Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis, Tuberk Toraks Lung, vol.54185, pp.173-181, 2006.

L. Lancaster, W. Mason, and J. Parnell, Obstructive Sleep Apnea Is Common in Idiopathic Pulmonary Fibrosis, Chest, vol.136, issue.3, pp.772-780, 2009.
DOI : 10.1378/chest.08-2776

C. Mermigkis, I. Bouloukaki, and K. Antoniou, Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis, Sleep and Breathing, vol.61, issue.1, pp.385-91, 2015.
DOI : 10.1111/j.1742-1241.2006.01213.x

F. Series, Y. Cormier, and N. Lampron, Increasing the functional residual capacity may reverse obstructive sleep apnea, Sleep, vol.11, pp.349-53, 1988.

R. Heinzer, M. Stanchina, and A. Malhotra, Lung Volume and Continuous Positive Airway Pressure Requirements in Obstructive Sleep Apnea, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.1, pp.114-121, 2005.
DOI : 10.1164/ajrccm.150.2.8049832

. Société-de-pneumologie-de-langue-française, Société française d'anesthésie réanimation, Société française de cardiologie SFdMdT, Société française d'ORL, Société de physiologie , Société française de recherche et de médecine du sommeil. Recommandations pour la pratique clinique. Syndrome d'apnées hypopnées obstructives du sommeil de l'adulte, Rev Mal Respir, vol.27, pp.806-839, 2010.

R. Hubbard, A. Venn, and S. Lewis, Lung Cancer and Cryptogenic Fibrosing Alveolitis, American Journal of Respiratory and Critical Care Medicine, vol.161, issue.1, pp.5-8, 2000.
DOI : 10.1164/ajrccm.154.2.8756825

M. Turner-warwick, B. Burrows, and A. Johnson, Cryptogenic fibrosing alveolitis: clinical features and their influence on survival, Thorax, vol.35, issue.3, pp.171-80, 1980.
DOI : 10.1136/thx.35.3.171

J. Harris, I. Johnston, and R. Rudd, Cryptogenic fibrosing alveolitis and lung cancer: the BTS study, Thorax, vol.65, issue.1, pp.70-76, 2010.
DOI : 10.1136/thx.2009.121962

Y. Ozawa, T. Suda, and T. Naito, Cumulative incidence of and predictive factors for lung cancer in IPF, Respirology, vol.164, issue.5, pp.723-731, 2009.
DOI : 10.1164/ajrccm.164.7.2003140

S. Tomassetti, C. Gurioli, and J. Ryu, The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis, Chest, vol.147, issue.1, pp.157-64, 2015.
DOI : 10.1378/chest.14-0359

M. Kreuter, S. Ehlers-tenenbaum, and K. Palmowski, Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis, PLOS ONE, vol.161, issue.2, p.151425, 2016.
DOI : 10.1371/journal.pone.0151425.s002

N. Girard, S. Marchand-adam, and J. Naccache, Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Series of 47 Western Patients, Journal of Thoracic Oncology, vol.9, issue.8, pp.1162-70, 2014.
DOI : 10.1097/JTO.0000000000000209
URL : https://hal.archives-ouvertes.fr/hal-01063912

S. Oh, M. Kim, and J. Kim, Evolving Early Lung Cancers Detected During Follow-Up of Idiopathic Interstitial Pneumonia: Serial CT Features, American Journal of Roentgenology, vol.204, issue.6, pp.1190-1196, 2015.
DOI : 10.2214/AJR.14.13587

C. Fell, Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities, Clinics in Chest Medicine, vol.33, issue.1, pp.51-58, 2012.
DOI : 10.1016/j.ccm.2011.12.005

T. Sato, S. Teramukai, and H. Kondo, Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer, The Journal of Thoracic and Cardiovascular Surgery, vol.147, issue.5, pp.1604-1615, 2014.
DOI : 10.1016/j.jtcvs.2013.09.050

T. Iwata, S. Yoshida, and K. Nagato, Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis, Surgery Today, vol.158, issue.10, pp.1263-70, 2015.
DOI : 10.1164/ajrccm.158.5.9803115

N. Ueki, Y. Matsuo, and Y. Togashi, Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer, Journal of Thoracic Oncology, vol.10, issue.1, pp.116-141, 2015.
DOI : 10.1097/JTO.0000000000000359

S. Yamaguchi, T. Ohguri, and S. Ide, Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis, Lung Cancer, vol.82, issue.2, pp.260-265, 2013.
DOI : 10.1016/j.lungcan.2013.08.024

A. Sekine, K. Tamura, and H. Satoh, Prevalence of underlying lung disease in smokers with epidermal growth factor receptor-mutant lung cancer, Oncology Reports, vol.29, issue.5, 2013.
DOI : 10.3892/or.2013.2320

K. Usui, T. Ushijima, and Y. Tanaka, The frequency of epidermal growth factor receptor mutation of non small cell lung cancer according to the underlying pulmonary diseases, Pulm Med, p.290132, 2011.

D. Fujimoto, K. Tomii, and T. Otoshi, Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma, Lung Cancer, vol.80, issue.2, pp.159-64, 2013.
DOI : 10.1016/j.lungcan.2013.01.017

A. Primiani, D. Dias-santagata, and A. Iafrate, Pulmonary adenocarcinoma mutation profile in smokers with smokingrelated interstitial fibrosis, Int J Chron Obstruct Pulmon Dis, vol.9, pp.525-556, 2014.

W. Qi, Y. Sun, and Z. Shen, Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials, Journal of Chemotherapy, vol.4, issue.3, pp.40-51, 2015.
DOI : 10.1200/JCO.2007.15.6695

M. Burotto, E. Manasanch, and J. Wilkerson, Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials, The Oncologist, vol.20, issue.4, pp.400-410, 2015.
DOI : 10.1634/theoncologist.2014-0154

T. Shukuya, T. Ishiwata, and M. Hara, Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease, Anticancer Res, vol.30, pp.4357-61, 2010.

Y. Minegishi, J. Sudoh, and H. Kuribayasi, The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias, Lung Cancer, vol.71, issue.1, pp.70-74, 2011.
DOI : 10.1016/j.lungcan.2010.04.014

K. Okuda, T. Hirose, and Y. Oki, Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease, Anticancer Res, vol.32, pp.5475-80, 2012.

N. Watanabe, H. Taniguchi, and Y. Kondoh, Efficacy of Chemotherapy for Advanced Non-Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis, Respiration, vol.85, issue.4, pp.326-357, 2013.
DOI : 10.1159/000342046

R. Shimizu, D. Fujimoto, and R. Kato, The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease, Cancer Chemotherapy and Pharmacology, vol.211, issue.2, pp.1159-66, 2014.
DOI : 10.1148/radiology.211.2.r99ma01555

M. Choi, J. Hong, and W. Chang, Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease, Cancer Chemotherapy and Pharmacology, vol.183, issue.Suppl 2, pp.1217-1242, 2014.
DOI : 10.1164/rccm.2009-040GL

H. Kenmotsu, T. Naito, and M. Kimura, The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer, Journal of Thoracic Oncology, vol.6, issue.7, pp.1242-1248, 2011.
DOI : 10.1097/JTO.0b013e318216ee6b

Y. Minegishi, H. Kuribayashi, and K. Kitamura, The Feasibility Study of Carboplatin Plus Etoposide for Advanced Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias, Journal of Thoracic Oncology, vol.6, issue.4, pp.801-808, 2011.
DOI : 10.1097/JTO.0b013e3182103d3c

T. Yoshida, K. Yoh, and K. Goto, Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease, Anticancer Res, vol.33, pp.1175-1184, 2013.

N. Watanabe, H. Taniguchi, and Y. Kondoh, Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis, International Journal of Clinical Oncology, vol.177, issue.2, pp.260-265, 2014.
DOI : 10.1164/ajrccm.177.12.1397a

K. Miyazaki, H. Satoh, and K. Kurishima, Interstitial lung disease in patients with small cell lung cancer, Medical Oncology, vol.19, issue.3 Suppl, pp.763-770, 2010.
DOI : 10.1016/j.clon.2007.01.112

Y. Togashi, K. Masago, and T. Handa, Prognostic Significance of Preexisting Interstitial Lung Disease in Japanese Patients With Small-Cell Lung Cancer, Clinical Lung Cancer, vol.13, issue.4, pp.304-315, 2012.
DOI : 10.1016/j.cllc.2011.11.001

G. Raghu, V. Amatto, and J. Behr, Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review, European Respiratory Journal, vol.46, issue.4, pp.1113-1143, 2015.
DOI : 10.1183/13993003.02316-2014

C. Vancheri, V. Cottin, and M. Kreuter, IPF, comorbidities and management implications, Sarcoidosis Vasc Diffuse Lung Dis, vol.32, pp.17-23, 2015.

C. Hyldgaard, O. Hilberg, and E. Bendstrup, How does comorbidity influence survival in idiopathic pulmonary fibrosis?, Respiratory Medicine, vol.108, issue.4, pp.647-53, 2014.
DOI : 10.1016/j.rmed.2014.01.008

V. Navaratnam, A. Fogarty, and T. Mckeever, Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case???control study, Thorax, vol.168, issue.(Pt 1), pp.207-222, 2014.
DOI : 10.1164/rccm.2201082

H. Collard, A. Ward, and S. Lanes, Burden of illness in idiopathic pulmonary fibrosis, Journal of Medical Economics, vol.15, issue.5, pp.829-864, 2012.
DOI : 10.3111/13696998.2012.680553

M. Armanios and C. Price, Telomeres and disease: An overview, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.730, issue.1-2, pp.1-2, 2012.
DOI : 10.1016/j.mrfmmm.2011.11.005

S. Stanley, D. Gable, and C. Wagner, Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema, Science Translational Medicine, vol.7, issue.suppl_1, pp.351-107, 2016.
DOI : 10.1093/nar/gkj002

B. Stuart, J. Choi, and S. Zaidi, Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening, Nature Genetics, vol.47, issue.5, pp.512-519, 2015.
DOI : 10.1086/302662

C. Kannengiesser, R. Borie, and C. Menard, mutations are associated with familial pulmonary fibrosis, European Respiratory Journal, vol.46, issue.2, pp.474-85, 2015.
DOI : 10.1183/09031936.00040115
URL : https://hal.archives-ouvertes.fr/hal-01214563

U. Hodgson, V. Pulkkinen, and M. Dixon, ELMOD2 Is a Candidate Gene for Familial Idiopathic Pulmonary Fibrosis, The American Journal of Human Genetics, vol.79, issue.1, pp.149-54, 2006.
DOI : 10.1086/504639

A. Zamora, H. Collard, and P. Wolters, Neurofibromatosis-associated lung disease: a case series and literature review, European Respiratory Journal, vol.29, issue.1, pp.210-214, 2007.
DOI : 10.1183/09031936.06.00044006

A. Hamvas, R. Deterding, and S. Wert, Heterogeneous Pulmonary Phenotypes Associated With Mutations in the Thyroid Transcription Factor Gene NKX2-1, Chest, vol.144, issue.3, pp.794-804, 2013.
DOI : 10.1378/chest.12-2502

E. Dell-'angelica, V. Shotelersuk, and R. Aguilar, Altered Trafficking of Lysosomal Proteins in Hermansky-Pudlak Syndrome Due to Mutations in the ??3A Subunit of the AP-3 Adaptor, Molecular Cell, vol.3, issue.1, pp.11-21, 1999.
DOI : 10.1016/S1097-2765(00)80170-7

S. Mercier, S. Kury, and G. Shaboodien, Mutations in FAM111B Cause Hereditary Fibrosing Poikiloderma with Tendon Contracture, Myopathy, and Pulmonary Fibrosis, The American Journal of Human Genetics, vol.93, issue.6, pp.1100-1107, 2013.
DOI : 10.1016/j.ajhg.2013.10.013